Previous 10 | Next 10 |
PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no serious adverse events associated with them in Phase II clinical trial Company is...
· Dr. Andrew Chang, principal investigator, recently presented encouraging feasibility study results from Vitargus® at the AAO 2019 Annual Meeting · Study results sugges...
· Dr. Andrew Chang, principal investigator, recently presented encouraging feasibility study results from Vitargus® at the AAO 2019 Annual Meeting · Study results s...
· Dr. Andrew Chang, principal investigator, will present encouraging results on Vitargus® from recently completed feasibility study · Company to initiate multi-national,...
· Dr. Andrew Chang, principal investigator, will present encouraging results on Vitargus® from recently completed feasibility study · Company to initiate multi-nati...
American BriVision ( OTCQB:ABVC -2.2% ) announced that as of September 1, Mr. Chihliang “Andy” An was appointed as the Company’s new CFO. More news on: American BriVision (Holding) Corporation, Read more ...
FREMONT, CA, Oct. 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to ...
Fremont, CA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American BriVision (Holding) Corporation (OTCQB: ABVC ) (the “Company”), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, toda...
American BriVision ( OTCQB:ABVC -0.2% ) inks an exclusive global research collaboration and license agreement with BioLite Japan aimed at identifying early-stage opportunities in drug development, digital health and medical device technology. More news on: American BriVision (Holding) ...
Collaboration combines BioLite Japan’s early-stage discovery capabilities with the Company’s clinical trial expertise BioLite Japan’s expertise in academic and medical community in Japan and APAC region brings new development candidates to ...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will i...
FREMONT, CA - ( NewMediaWire ) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II c...
FREMONT, CA - ( NewMediaWire ) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and it...